Bevacizumab and thrombosis risk in cancer patients with COVID-19: A national retrospective cohort study (TIC-TAC)
Background Cancer patients treated with bevacizumab are at increased risk of thromboembolic events. COVID-19 is also associated with thromboembolism, but its impact on thromboembolic risk in cancer patients receiving bevacizumab remains unclear. The TIC-TAC study aimed to assess whether COVID-19 diagnosis is associated with an increased risk of venous thromboembolic events (VTE) within 30 days or arterial (ATE) thromboembolic events within 90 days in this population. Methods A retrospective nationwide cohort study was conducted using the French national health data system. Cancer patients treated with bevacizumab between January 2019 and December 2021 were included. Bevacizumab exposures were used as statistical unit, and defined to 5 half-lives (100 days) after its administration. COVID-19 diagnosis was defined by ICD-10 codes or positive virological tests. The primary outcome was the occurrence of VTE or ATE during hospitalization. Cox models with time-dependent exposure and Fine and Gray competing-risk models were used to estimate hazard ratios (HR) and subdistribution hazard ratios (SHR), with death considered as a competing risk. Results Among 58,855 patients (median age 67 years, 79.9% with metastatic disease), 5,589 VTE and 1,926 ATE were recorded over 46,750 and 46,915 person-years, respectively. COVID-19 diagnosis was associated with a higher risk of VTE within 30 days after diagnosis in crude (HR 1.89, 95% CI 1.55–2.29) and adjusted Cox models (aHR 1.99 [1.64–2.43]), as well as in the Fine and Gray model (aSHR 1.70 [1.40–2.07]). However, the unadjusted absolute risk increase was modest: one additional VTE per 64.6 person-months of COVID-19 exposure. A significant interaction between COVID-19 diagnosis and anticoagulant therapy was observed in the VTE Cox model (p = 0.007), but not in the Fine and Gray model. No significant association was found between COVID-19 diagnosis and ATE risk. Conclusion The study showed that 30 days period after a COVID-19 diagnosis could be associated with an increased risk of VTE in cancer patients treated with bevacizumab. However, the absolute risk difference, although unadjusted and therefore uncertain, appeared modest. Causality cannot be established in this retrospective design. No significant association was observed for ATE.
Authors
- Leslie Grammatico‐Guillon (ORCID: https://orcid.org/0000-0001-7934-8912)
- Émeline Laurent (ORCID: https://orcid.org/0000-0002-0995-8376)
- Thierry Lecomte (ORCID: https://orcid.org/0000-0001-5093-0212)
- Romain Chautard (ORCID: https://orcid.org/0000-0001-6030-5621)
- Pascal Vigny (ORCID: https://orcid.org/0009-0006-2218-9782)
- Adrien Migeon
- Anne-Isabelle LECUYER
- Hugo DESMARS
Institutions
- Université de Tours (FR)
- Centre Hospitalier Universitaire de Tours (FR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1371/journal.pone.0362952
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00